$-0.07 EPS Expected for Zumiez Inc. (ZUMZ); Ligand Pharmaceuticals (LGND)’s Sentiment Is 1.2

August 26, 2017 - By Peter Erickson

Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has market cap of $2.55 billion. The Firm is involved in the development and licensing of biopharmaceutical assets. It has a 328.4 P/E ratio. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Analysts expect Zumiez Inc. (NASDAQ:ZUMZ) to report $-0.07 EPS on September, 14.They anticipate $0.04 EPS change or 133.33% from last quarter’s $-0.03 EPS. After having $-0.18 EPS previously, Zumiez Inc.’s analysts see -61.11% EPS growth. The stock increased 3.46% or $0.45 on August 25, reaching $13.45. About 459,229 shares traded or 7.37% up from the average. Zumiez Inc. (NASDAQ:ZUMZ) has risen 3.10% since August 26, 2016 and is uptrending. It has underperformed by 13.60% the S&P500.

Knott David M holds 51.04% of its portfolio in Ligand Pharmaceuticals Inc. for 998,100 shares. Rk Capital Management Llc owns 191,883 shares or 4.04% of their US portfolio. Moreover, Cardinal Capital Management Llc Ct has 3.35% invested in the company for 767,485 shares. The Minnesota-based Kopp Investment Advisors Llc has invested 2.55% in the stock. Ashford Capital Management Inc, a Delaware-based fund reported 120,409 shares.

Since January 1, 0001, it had 0 buys, and 6 sales for $7.71 million activity.

The stock decreased 2.20% or $2.79 on August 25, reaching $124.05. About 192,653 shares traded. Ligand Pharmaceuticals Inc. (LGND) has declined 2.87% since August 26, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Investors sentiment increased to 1.62 in 2016 Q4. Its up 0.77, from 0.85 in 2016Q3. It increased, as 12 investors sold Zumiez Inc. shares while 35 reduced holdings. 35 funds opened positions while 41 raised stakes. 19.96 million shares or 0.57% more from 19.85 million shares in 2016Q3 were reported. Sei Invests invested in 57 shares. Td Asset Mngmt stated it has 51,120 shares or 0% of all its holdings. Tower Research Lc (Trc) stated it has 2,253 shares. Invesco reported 0% stake. Teachers Retirement Sys Of The State Of Kentucky has invested 0% in Zumiez Inc. (NASDAQ:ZUMZ). Dimensional Fund Advisors Lp invested in 0.02% or 1.82M shares. Systematic Financial Mgmt L P reported 0.06% in Zumiez Inc. (NASDAQ:ZUMZ). Legal General Grp Pcl has invested 0% in Zumiez Inc. (NASDAQ:ZUMZ). Blackrock Institutional Trust Co Na reported 492,030 shares. Hanseatic Mgmt Serv Incorporated stated it has 13,152 shares. Geode Cap Management Ltd Com holds 0% of its portfolio in Zumiez Inc. (NASDAQ:ZUMZ) for 152,135 shares. Vanguard Gp Inc has 0% invested in Zumiez Inc. (NASDAQ:ZUMZ) for 1.52 million shares. Swiss Comml Bank owns 33,300 shares or 0% of their US portfolio. Point72 Asset Management L P has 0.05% invested in Zumiez Inc. (NASDAQ:ZUMZ) for 301,200 shares. The New York-based has invested 0% in Zumiez Inc. (NASDAQ:ZUMZ).

Among 20 analysts covering Zumiez Inc. (NASDAQ:ZUMZ), 4 have Buy rating, 2 Sell and 14 Hold. Therefore 20% are positive. Zumiez Inc. had 53 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, August 6 by Sterne Agee CRT. The company was maintained on Thursday, August 6 by Roth Capital. Topeka Capital Markets maintained the stock with “Buy” rating in Friday, September 11 report. The stock has “Neutral” rating by Mizuho on Thursday, October 6. The firm has “Neutral” rating by SunTrust given on Thursday, August 4. The stock of Zumiez Inc. (NASDAQ:ZUMZ) has “Hold” rating given on Friday, June 2 by Jefferies. Stifel Nicolaus maintained the stock with “Hold” rating in Thursday, October 6 report. The firm earned “Neutral” rating on Thursday, October 6 by Robert W. Baird. The rating was maintained by Sterne Agee CRT on Friday, September 11 with “Fairly Valued”. B. Riley & Co downgraded it to “Neutral” rating and $25 target in Thursday, December 22 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com